Efficacy and Safety Exploration of Short Course Radiotherapy Followed by Surufatinib and Toripalimab in Neoadjuvant Treatment of Locally Advanced Rectal Cancer (STARS-RC08)
Why is this study conducted? The purpose of this study is to improve treatment efficacy, particularly the pathological complete response rate, in patients with high-risk/extremely high-risk locally advanced rectal cancer (LARC). While advances have been achieved with neoadjuvant chemoradiotherapy combined with immunotherapy in recent years, regional recurrence and distant metastasis remain unresolved. New therapeutic strategies for this patient population are therefore urgently needed.
Rectal cancer management typically includes surgery, radiation therapy and chemotherapy. Treatment paradigms are shifting toward neoadjuvant chemoradiotherapy plus immunotherapy, which has demonstrated promising potential in several clinical trials. These data indicate that short-course radiotherapy combined with anti-angiogenic agents and immune checkpoint inhibitors may improve patient prognosis and tumor response. Nevertheless, the efficacy and safety of this regimen in high-risk patients require further validation.
Against this background, the study evaluates a novel regimen of short-course radiotherapy followed by surufatinib and toripalimab (anti-PD-1) to raise the pathological complete response rate. The investigators also explore efficacy-related biomarkers including RAS/BRAF status and gene expression profiles to support personalized treatment. This study aims to optimize therapy for LARC patients and inform future treatment strategies.
Why are participants invited to participate in this study? Participants are considered eligible for enrollment upon diagnosis of high-risk or extremely high-risk locally advanced rectal cancer consistent with study inclusion criteria. Eligibility requires confirmed pathological diagnosis, appropriate tumor location, and absence of severe comorbidities or exclusionary diseases (e.g., recurrent rectal cancer, cardiac dysfunction). Final enrollment decisions are made by study physicians based on individual clinical conditions.
What do participants need to do to participate in this study? Study participation requires adherence to predefined procedures. Participants receive scheduled medical assessments including blood tests, imaging scans and anorectal function evaluation. During the study period, participants may complete questionnaires and provide biospecimens (e.g., blood samples) for efficacy analysis. The study team defines the frequency and content of each follow-up to maintain continuous monitoring throughout treatment. Compliance with study procedures supports evaluation of regimen efficacy.
What are the risks of participating in this study?
This study applies neoadjuvant short-course radiotherapy, anti-PD-1 monoclonal antibody (toripalimab), and anti-angiogenic therapy (surufatinib). Potential risks for participants are listed below:
Risk of neoadjuvant short-course radiotherapy: Participants may develop grade ≥3 adverse events including, but not limited to, severe diarrhea, grade 3 neutropenia and grade 3 radiation dermatitis, which may impair quality of life.
Risk of anti-PD-1 monoclonal antibody: Toripalimab may induce immune-related adverse events (irAEs) across organ systems. Common irAEs include skin toxicity (papules, pruritus; incidence 30%-40%), diarrhea/colitis (8%-19%), fatigue (16%-24%), immune-related hepatitis (5%), hypothyroidism (4%-10%), and hyperthyroidism (4%). Approximately two-thirds of patients receiving immune checkpoint inhibitors develop irAEs of varying severity, and serious adverse events are non-negligible.
Risk of anti-angiogenic therapy: Surufatinib may trigger adverse events related to anti-angiogenic and immunomodulatory effects. Common adverse events (incidence >20%) include proteinuria, hypertension, bleeding, liver dysfunction and diarrhea. Among grade ≥3 adverse events, hypertension (29.7%), proteinuria (14.5%), liver dysfunction (12.8%) and bleeding (4.5%) predominate. Rarely, treatment-related death may occur secondary to gastrointestinal hemorrhage or cerebral hemorrhage.
Handling of research related injuries? This interventional study introduces no extra risks beyond standard clinical care. Any harm arising from study participation will be addressed for compensation and liability in accordance with applicable laws and regulations.
研究概览
详细说明
Why is this study conducted? The purpose of this study is to improve treatment efficacy, particularly the pathological complete response rate, in patients with high-risk/extremely high-risk locally advanced rectal cancer (LARC). Recent advances have been achieved with neoadjuvant chemoradiotherapy combined with immunotherapy for rectal cancer, yet regional recurrence and distant metastasis remain persistent challenges. Developing novel therapeutic strategies for this patient population is therefore critical.
Rectal cancer management typically consists of surgery, radiation therapy, and chemotherapy. Treatment strategies are gradually shifting toward neoadjuvant chemoradiotherapy plus immunotherapy, which has demonstrated promising potential in multiple clinical trials. These trials indicate that combining short-course radiotherapy, anti-angiogenic agents, and immune checkpoint inhibitors may improve patient prognosis and increase tumor response rates. Nonetheless, the efficacy and safety of such regimens in high-risk patients require further validation.
Against this background, the study aims to evaluate a novel regimen: short-course radiotherapy followed by surufatinib and toripalimab (anti-PD-1), to increase the pathological complete response rate. The investigators also explore efficacy-associated biomarkers including RAS/BRAF status and gene expression profiles to support personalized treatment. This study seeks to optimize therapy for patients with LARC and inform future treatment approaches.
Why are participants invited to participate in this study? Participants are eligible for screening with a diagnosis of high-risk or extremely high-risk locally advanced rectal cancer that satisfies study inclusion criteria. Eligible candidates must have pathologically confirmed disease, appropriate tumor location, and no severe comorbidities or exclusionary illnesses (e.g., recurrent rectal cancer, cardiac dysfunction). Final enrollment decisions are made by study physicians based on individual clinical status.
What do participants need to do to participate in this study? Study participation requires adherence to predefined study procedures. Participants receive scheduled medical assessments, including blood tests, imaging scans, and anorectal function evaluations. During the study period, participants may complete questionnaires and provide biospecimens (e.g., blood samples) for treatment efficacy analysis. The study team defines the frequency and content of each follow-up to maintain continuous monitoring throughout treatment. Compliance with study procedures supports evaluation of regimen efficacy.
What are the risks of participating in this study?
This study applies neoadjuvant short-course radiotherapy, anti-PD-1 monoclonal antibody (toripalimab), and anti-angiogenic therapy (surufatinib). Potential risks for participants are listed below:
Risk of neoadjuvant short-course radiotherapy: Participants may develop grade ≥3 adverse events including, but not limited to, severe diarrhea, grade 3 neutropenia, and grade 3 radiation dermatitis, which may impair patient quality of life.
Risk of anti-PD-1 monoclonal antibody: Toripalimab may induce immune-related adverse events (irAEs) involving any organ system. Common irAEs include skin toxicity (papules, pruritus; incidence 30% to 40%), diarrhea and/or colitis (8% to 19%), fatigue (16% to 24%), immune-related hepatitis (5%), hypothyroidism (4% to 10%), and hyperthyroidism (4%). Approximately two-thirds of patients receiving immune checkpoint inhibitors develop irAEs of varying severity; the risk of serious adverse events cannot be overlooked.
Risk of anti-angiogenic therapy: Surufatinib may trigger adverse reactions related to its anti-angiogenic and immunomodulatory effects. Common adverse events (incidence >20%) include proteinuria, hypertension, bleeding, liver dysfunction, and diarrhea. Among grade ≥3 adverse events, hypertension (29.7%), proteinuria (14.5%), liver dysfunction (12.8%), and bleeding (4.5%) occur most frequently. Rarely, treatment-related death may result from gastrointestinal hemorrhage or cerebral hemorrhage.
Handling of research related injuries? This interventional study introduces no incremental risks beyond standard clinical diagnosis and treatment. Any harm arising from study participation will be reviewed for compensation and liability in accordance with applicable laws and regulations.
研究类型
注册 (估计的)
阶段
- 阶段2
- 第三阶段
联系人和位置
学习联系方式
- 姓名:pengyu Chang, Doctor
- 电话号码:+86-18686653882
- 邮箱:changpengyu@jlu.edu.cn
学习地点
-
-
Jilin
-
Changchun、Jilin、中国、130000
- 招聘中
- the first hospital of Jilin University
-
接触:
- Pengyu Chang
- 电话号码:+86-18686653882
- 邮箱:changpengyu@jlu.edu.cn
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 18-75 years, male or female
- Pathologically confirmed rectal tubular adenocarcinoma, Grade 1 (well), Grade 2 (moderate), or Grade 3 (poor) differentiation; pMMR phenotype
- Mid or low rectal cancer with the lower tumor margin within 10 cm of the anal verge
- Treatment-naive disease with high-risk features including cT4, cN2, MRF+, or EMVI+; and/or mrLR4 disease with impossible anal preservation or mrLR3 disease with difficult anal preservation at baseline assessment
- No evidence of distant metastasis
- ECOG performance status 0-1
Exclusion Criteria:
- Recurrent rectal cancer
- ECOG performance status ≥2
- Other organ diseases that create unacceptable treatment risk (refer to the protocol for full exclusion criteria)
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:short course radiotherapy followed by surufatinib and toripalimab in locally advanced rectal cancer
|
Short-course preoperative radiotherapy (SCRT) for locally advanced rectal cancer. Toripalimab 200 mg will be administered intravenously once every 21 days for 4 cycles. Surufatinib 250 mg will be orally administered once daily during the first 3 cycles concurrently with toripalimab. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pathologic complete response (pCR) rate
大体时间:From baseline up to the time of surgery (approximately 14 weeks after radiotherapy initiation)
|
Pathologic complete response (pCR) rate is defined as the percentage of patients who achieve pCR after neoadjuvant therapy within the eligible population [15]. Pathologic complete response (pCR) is characterized by the absence of invasive cancer in the primary rectum and negative regional lymph nodes following adequate or complete sampling (ypT0N0, tumor regression grade [TRG] 0 points) [16]. Microscopically, cancer cells in the tumor bed are absent, with possible infiltration of inflammatory cells in the interstitium. Additionally, foamy cells and fibrous tissue proliferation may be observed. (For evaluation criteria, refer to the AJCC 8th Edition: Colorectal Cancer.) |
From baseline up to the time of surgery (approximately 14 weeks after radiotherapy initiation)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.